Skip to main content

Table 2 Patients’ characteristics with non-metastatic gastric cancer

From: A randomized, double-blind, placebo-controlled investigation of BCc1 nanomedicine effect on survival and quality of life in metastatic and non-metastatic gastric cancer patients

  BCc1 nanomedicine
(n = 30)
Placebo
(n = 30)
Age, years
 Mean (SD) 65 ± 10.5 61 ± 11.4
Weight
 Mean (SD) 62 ± 14 59 ± 11
Gender (n)
 Male–female 20–10 14–19
Stage (n)
 I 3 1
 II 3 8
 III 19 13
Site of involvement (n)
 Cardia 10 9
 Antrum 9 6
 Fundus 0 3
 Greater curvature 3 1
 Lesser curvature 7 5
 Diffuse 2 2
Intervention + chemotherapy (n) 12 20
Intervention chemotherapy + radiotherapy (n) 1 2